Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 13/20 | 0.36 |
| ▸ | CDK9 | P50750 | 13/20 | 0.36 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.35 |
| ▸ | PGR | P06401 | 2/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23875018 | 0.85 | CCNT1 (0.35) | CCNT1CDK9NR3C1PGRNR3C2 | |
| SCHEMBL21885734 | 0.84 | CCNT1 (0.42) | CCNT1CDK9SLC9A1PGRALDH1A1 | |
| SCHEMBL21884444 | 0.79 | PYGL (0.40) | SLC9A1KDM4EALDH1A1 | |
| SCHEMBL21884621 | 0.75 | CCNT1 (0.34) | CCNT1CDK9 | |
| SCHEMBL23854842 | 0.75 | PPIA (0.35) | CCNT1CDK9SLC9A1PGRALDH1A1 | |
| SCHEMBL23854863 | 0.74 | CCNT1 (0.41) | CCNT1CDK9ALDH1A1 | |
| SCHEMBL21884382 | 0.73 | ALDH1A1 (0.37) | CCNT1CDK9KDM4EPGRALDH1A1 | |
| SCHEMBL21884375 | 0.73 | ALDH1A1 (0.40) | CCNT1CDK9PGRALDH1A1 | |
| SCHEMBL21884581 | 0.73 | KCNMA1 (0.42) | SLC9A1KDM4EPGRALDH1A1 | |
| SCHEMBL23854878 | 0.72 | CCNT1 (0.41) | CCNT1CDK9SLC9A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| WO-2020061473-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | SLC19A1, SLC1A5, SLC1A2 | CCNT1 4085/4885CDK9 4006/4885SLC9A1 125/4885 |
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | SNRPE, G3BP1, G3BP2 | CCNT1 4017/4885CDK9 2832/4885SLC9A1 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.